Turn to the nation's most objective and informative daily environmental news resource to learn how the United States and key players around the world are responding to the environmental...
A long-term survey of tens of thousands of U.S. farmers found no significant link between cancer and exposure to glyphosate, best known as the main ingredient in Monsanto Co.'s Roundup herbicide.
But the study shines a light on previously neglected areas, and could lead to further inquiry into the link between glyphosate and an uncommon form of leukemia, one of the paper’s authors said.
The paper, published in the Journal of the National Cancer Institute Nov. 9, marks the first update in 12 years to the continuous national Agricultural Health Study (AHS) of farmers. The findings are consistent with the last paper from the AHS, which also found no correlation between the controversial weedkiller and cancer.
However, scientists did find a more than twofold increase in cases of acute myeloid leukemia (AML), a rare cancer of the blood, for the most exposed farmers compared with those who never sprayed glyphosate.
This finding is not statistically significant, Laura Beane Freeman, co-author of the paper, said because of the small number of AML cases. But it signals a need for further study of the matter.
“There’s definitely a need to look at glyphosate in other exposed populations,” Freeman, an epidemiologist with the National Cancer Institute, told Bloomberg Environment. “I think replication of this [AML] finding in other populations is probably the most important thing to do.”
The study results are the best example of how glyphosate affects farmers and their spouses in the real world, according to Scott Partridge, Monsanto’s vice president of global strategy.
“It is the gold standard. It conclusively demonstrates that there is no association between the exposure, use of glyphosate, and cancer,” Partridge told Bloomberg Environment.
The National Cancer Institute began tracking farmers and their families in 1993 to measure their exposure to a number of pesticides and other environmental factors, and the incidence of cancer. It’s the largest study of its kind in the world.
The latest paper counted and studied more than 54,000 farmers in North Carolina and Iowa. The institute released findings in 2005 from the survey that also found no strong link between glyphosate exposure and cancer.
The latest paper includes more than three times the cancer cases found in the 2005 results—7,290 compared to 2,088.
The paper also marks the first time the institute could analyze different types of leukemia, Freeman said.
The size of the study gives it importance, John Yu, an assistant professor in the University of Georgia’s Department of Environmental Health Science, told Bloomberg Environment. But it has some weaknesses.
The paper measures exposure only by the days and years a person was around glyphosate, but doesn’t take into account measures to protect oneself, such as wearing protective clothing. It also doesn’t mention exposure to other pesticides, which can be a confounding factor, Yu said.
News of the findings of the paper hit headlines months before its official release. In June, legal documents surfaced indicating that the senior scientist in charge of the AHS, Aaron Blair, thought the AHS findings could have led to a different outcome on a controversial scientific finding on glyphosate.
In 2015, the International Agency for Research on Cancer assessed the scientific literature on the weedkiller and found it to “probably” cause non-Hodgkins lymphoma, a cancer of the lymphatic system. IARC didn’t look at the latest AHS data to come to its determination, even though it was complete, because it hadn’t been published in a scientific journal.
The conclusion put the spotlight on a chemical that has been treated as a relatively safe herbicide by regulators around the world. Monsanto launched a campaign to discredit IARC’s monograph, or assessment of the substance.
Recent reports also indicate that IARC favored certain studies that showed an association between glyphosate and cancer.
“It’s time now for IARC to withdraw that monograph,” Partridge of Monsanto said.
Freeman disagrees that the latest study would have moved the needle on IARC’s decision. The agency had access to the published 2005 report, which came to the same conclusion as the latest one: glyphosate exposure does not result in higher cancer rates.
“They had full access to the 2005 paper that showed no association,” Freeman said.
Although Monsanto is the original maker of glyphosate, dozens of companies now make it. As of 2010, more than 750 glyphosate products were sold in the U.S., and it was registered for use in more than 130 countries, according to the paper.
The current 15-year authorization to let farmers continue to use glyphosate in the 28-nation European Union expires Dec. 15.
But a sufficiently large bloc of countries opposed a compromise five-year reauthorization in a regulatory committee vote Nov. 9, meaning the decision will be kicked to another committee meeting before the end of November.
To contact the reporter on this story: Tiffany Stecker in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Rachael Daigle at email@example.com
The Journal of the National Cancer Institute study is here: http://src.bna.com/t7S
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)